News & Updates
Filter by Specialty:
![[test headline bait]Amivantamab plus chemo tied to better outcomes in NSCLC](https://sitmspst.blob.core.windows.net/images/articles/amivantamab-plus-chemo-tied-to-better-outcomes-vs-chemo-alone-in-advanced-nsclc-4c5757ec-0008-423f-84f1-77e75dacf343-square.jpg)
[test headline bait]Amivantamab plus chemo tied to better outcomes in NSCLC
Treatment with amivantamab (ami) in combination with chemotherapy (chemo) results in substantially longer time to treatment discontinuation (TTD), time to subsequent therapy (TTST), and progression-free survival (PFS) after first subsequent therapy (PFS2) in patients with EGFR-mutant advanced nonsmall cell lung cancer (NSCLC) following progression on osimertinib, as shown in a postprogression analysis.
[test headline bait]Amivantamab plus chemo tied to better outcomes in NSCLC
17 Jul 2024
Novel agent plus ritonavir show favourable signals for mild-to-moderate COVID-19
A combination regimen comprising the novel agent GST-HG171 (also known as atilotrelvir) and ritonavir improves clinical symptom recovery and viral clearance in low-risk vaccinated adults with mild-to-moderate COVID-19, findings from a pivotal phase II/III study have shown.
Novel agent plus ritonavir show favourable signals for mild-to-moderate COVID-19
10 Jul 2024
Lung cancer screening tied to reduced mortality
In an observational study conducted in Poland, individuals who participated in a low-dose computed tomography (LDCT) lung cancer screening programme had a reduction in all-cause mortality compared with a matched control group extracted from a general Polish cohort.
Lung cancer screening tied to reduced mortality
02 Jul 2024
Neoadjuvant cycles do not alter perioperative nivolumab benefit in resectable NSCLC
Treatment with nivolumab plus chemotherapy before surgery followed by nivolumab after surgery yields superior outcomes for patients with resectable nonsmall cell lung cancer (NSCLC) as compared with placebo plus chemotherapy, regardless of the number of completed neoadjuvant cycles, according to an exploratory analysis of the CHECKMATE 77T trial.